ASCO Daily News | Ouvir podcast online grátis

310 episódios

ASCENT and DESTINY-Breast09 Trials: Applying Frontline Data in Metastatic Breast Cancer Care
15/10/2026 | 20min
Dr. Sara Tolaney joins Dr. Monty Pal to discuss optimizing the sequencing and combination of antibody-drug conjugates for metastatic HER2-positive and triple-negative breast cancer, as well as guidelines for managing serious toxicities like ILD and neutropenia.
LINK TO FULL TRANSCRIPT
CAR T Cells and Bispecific Antibodies: Navigating the New Era in Multiple Myeloma Management
01/10/2026 | 21min
Myeloma specialists Dr. Marc Braunstein and Dr. Rahul Banerjee join Dr. Monty Pal to discuss recent breakthroughs for patients with multiple myeloma, including expert advice on how to manage side effects and identify the right treatment among a series of novel immuno- and targeted therapies.
LINK TO FULL TRANSCRIPT
Are We Curing Advanced Melanoma? A Conversation With Dr. Jedd Wolchok
10/09/2026 | 20min
Dr. Jedd Wolchok, a pioneer in melanoma research, joins Dr. Monty Pal to break down practice-changing advances in the field, including landmark 10-year CheckMate-067 survival data, safer immunotherapy dosing, and the rise of neoadjuvant treatment.
LINK TO FULL TRANSCRIPT
Updates in Bladder Cancer: From Intravesical Breakthroughs to Managing Toxicities
03/09/2026 | 23min
Dr. Monty Pal and Dr. Petros Grivas discuss the rapidly evolving management of bladder cancer, including key updates in non-muscle-invasive disease, the integration of novel therapies in the advanced setting, and practical strategies for managing toxicities in clinical practice.
LINK TO FULL TRANSCRIPT
How Do We Translate ASCO26 Research Into Practice in Latin America?
20/08/2026 | 21min
In part two of our miniseries on the global translation gap in oncology, host Dr. Monty Pal and Dr. Regina Barragán-Carrillo explore how ASCO26 Plenary breakthroughs can be adapted to clinical practice in Latin America. Together, they address real-world implementation challenges including delayed diagnoses, finite resource allocation, and access to precision diagnostics.
LINK TO FULL TRANSCRIPT